Hierarchical models for probabilistic dose-response assessment.
暂无分享,去创建一个
R L Kodell | J J Chen | R R Delongchamp | J F Young | J. Chen | R. Kodell | J. F. Young | R. Delongchamp
[1] Bradley P. Carlin,et al. BAYES AND EMPIRICAL BAYES METHODS FOR DATA ANALYSIS , 1996, Stat. Comput..
[2] Harvey J Clewell,et al. Evaluation of Physiologically Based Pharmacokinetic Models in Risk Assessment: An Example with Perchloroethylene , 2005, Critical reviews in toxicology.
[3] P. Watanabe,et al. Resolution of dose-response toxicity data for chemicals requiring metabolic activation: example--vinyl chloride. , 1978, Toxicology and applied pharmacology.
[4] T. Starr,et al. Quantitative cancer risk estimation for formaldehyde. , 1990, Risk analysis : an official publication of the Society for Risk Analysis.
[5] C Eric Hack,et al. Bayesian analysis of physiologically based toxicokinetic and toxicodynamic models. , 2006, Toxicology.
[6] Paul M Schlosser,et al. Benchmark dose risk assessment for formaldehyde using airflow modeling and a single-compartment, DNA-protein cross-link dosimetry model to estimate human equivalent doses. , 2003, Risk analysis : an official publication of the Society for Risk Analysis.
[7] J Van Ryzin,et al. A dose-response model incorporating nonlinear kinetics. , 1987, Biometrics.
[8] D. Gaylor,et al. A mechanistic approach to modelling the risk of liver tumours in mice exposed to fumonisin B1 in the diet , 2001, Food additives and contaminants.
[9] Melvin E. Andersen,et al. Applying Mode-of-Action and Pharmacokinetic Considerations in Contemporary Cancer Risk Assessments: An Example with Trichloroethylene , 2004 .
[10] Division on Earth. Risk Assessment in the Federal Government: Managing the Process , 1983 .
[11] M E Andersen,et al. Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. , 1995, Toxicology letters.
[12] A. Gelman,et al. Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions , 1996 .
[13] D. Krewski,et al. Toxicological Risk Assessment , 2019 .
[14] R L Kodell,et al. Upper confidence limits on excess risk for quantitative responses. , 1993, Risk analysis : an official publication of the Society for Risk Analysis.
[15] David B. Dunson,et al. Improving Risk Assessment: Research Opportunities in Dose Response Modeling to Improve Risk Assessment , 2002 .
[16] Tony Cox,et al. The Impact of Cytochrome P450 2E1‐Dependent Metabolic Variance on a Risk‐Relevant Pharmacokinetic Outcome in Humans , 2003, Risk analysis : an official publication of the Society for Risk Analysis.
[17] Hugh A Barton,et al. Framework for Evaluation of Physiologically‐Based Pharmacokinetic Models for Use in Safety or Risk Assessment , 2004, Risk analysis : an official publication of the Society for Risk Analysis.
[18] Ralph L Kodell,et al. A probabilistic framework for non-cancer risk assessment. , 2007, Regulatory toxicology and pharmacology : RTP.
[19] John F. Young,et al. Analysis of Methylmercury Disposition in Humans Utilizing A PBPK Model and Animal Pharmacokinetic Data , 2001, Journal of toxicology and environmental health. Part A.
[20] Michael F. W. Festing,et al. Use of a Multistrain Assay Could Improve the NTP Carcinogenesis Bioassay , 1995 .
[21] F. A. Smith,et al. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.
[22] Notes on likelihood intervals and profiling , 2000 .